Related content

Therapie des Seminoms im Stadium I

By Schmidberger H.  

Der Onkologe, Vol. 14, Iss. 6, 2008-06 ,pp. : 618-624

Springer Publishing Company

Access to resources Recommend Favorite

Therapie des Nichtseminoms im Stadium I

By Langenkamp S.  

Der Onkologe, Vol. 14, Iss. 6, 2008-06 ,pp. : 569-574

Springer Publishing Company

Access to resources Recommend Favorite

Internationale Studie zum Hodentumor: AH 10/04 – Randomisierte Phase-III-Studie 1×BEP (Bleomycin, Etoposid, Cisplatin) im Vergleich zu 2×BEP bei Patienten mit einem nichtseminomatösen Hodentumor im klinischen Stadium I (,,high risk“)

By Rexer H.  

Der Onkologe, Vol. 12, Iss. 10, 2006-10 ,pp. : 1041-1042

Springer Publishing Company

Access to resources Recommend Favorite

DNA Index Reflects the Biological Behavior of Ovarian Carcinoma Stage I-IIa

By Schueler J.A.   Trimbos J.B.   Burg M.   Cornelisse C.J.   Hermans J.   Fleuren G.J.  

Gynecologic Oncology, Vol. 62, Iss. 1, 1996-07 ,pp. : 59-66

Academic Press

Access to resources Recommend Favorite

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

By Mita M. M.   Poplin E.   Britten C. D.   Tap W. D.   Rubin E. H.   Scott B. B.   Berk L.   Rivera V. M.   Loewy J. W.   Dodion P.   Haluska F.   Sarantopoulos J.   Mita A.   Tolcher A.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1104-1111

Oxford University Press

Access to resources Recommend Favorite